INS and Hyperglycemia: This 26-week, phase IIIb, open-label, multinational, parallel-group, randomized, treat-to-target, non-inferiority trial (with a 26-week extension) compared the efficacy and safety of degludec once daily with that of IDet once daily or twice daily, both in combination with mealtime insulin aspart (IAsp).14 In this patient population, at equivalent glycemic control, degludec was associated with a similar rate of hypoglycemia and significantly lower rates of hyperglycemia with ketosis and a 30% lower basal insulin dose, compared with IDet.14